Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pharmacokinetics of three proton pump inhibitors in Chinese subjects in relation to the CYP2C19 genotype.

European journal of clinical pharmacology - 1 Feb 2006

Qiao Hai-Ling, Hu Yu-Rong, Tian Xin, Jia Lin-Jing, Gao Na, Zhang Li-Rong, Guo Yu-Zhong

Abstract excerpt

OBJECTIVE: Omeprazole, lansoprazole and rabeprazole have been widely used as proton pump inhibitors (PPIs). They can be metabolized in the liver by CYP2C19, a polymorphic enzyme, and have a wide inter-individual variability with respect to drug response. In the investigation reported here, we exa...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to 2-Pyridinylmethylsulfinylbenzimidazoles
Share to Area Under Curve
Share to Cross-Over Studies

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytochrome P-450 CYP2C19

Share to Lansoprazole

Share to Omeprazole

Share to Proton Pump Inhibitors

Share to Rabeprazole

Source

Identifiers

PMID: 16402242
DOI: 10.1007/s00228-005-0063-1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-16402242-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacokinetics of three proton pump inhibitors in Chinese subjects in relation to the CYP2C19 genotype.PMID 16402242Read ↗

Pharmacokinetics of lansoprazole in Chinese healthy subjects in relation to CYP2C19 genotypes.Semantic proximity Read ↗

CYP2C19 genotype and pharmacokinetics of three proton pump inhibitors in healthy subjects.Semantic proximity Read ↗

Effects of CYP2C19 genetic polymorphism on the pharmacokinetics and pharmacodynamics of omeprazole in Chinese people.Semantic proximity Read ↗

Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies.Semantic proximity Read ↗

Pharmacodynamic effects and kinetic disposition of rabeprazole in relation to CYP2C19 genotype in healthy Chinese subjects.Semantic proximity Read ↗

Pharmacokinetics of the new proton pump inhibitor ilaprazole in Chinese healthy subjects in relation to CYP3A5 and CYP2C19 genotypes.Semantic proximity Read ↗

Effects of CYP2C19 polymorphism on the pharmacokinetics of lansoprazole and its main metabolites in healthy Chinese subjects.Semantic proximity Read ↗

Effect of CYP2C19 genetic polymorphism on pharmacokinetics and pharmacodynamics of a new proton pump inhibitor, ilaprazole.Semantic proximity Read ↗

Genetic polymorphism of CYP2C19 and lansoprazole pharmacokinetics in Japanese subjects.Semantic proximity Read ↗

A comparative study of proton-pump inhibitor tests for Chinese reflux patients in relation to the CYP2C19 genotypes.Semantic proximity Read ↗

Genetic polymorphism of CYP2C19 in a Jordanian population: influence of allele frequencies of CYP2C19*1 and CYP2C19*2 on the pharmacokinetic profile of lansoprazole.Semantic proximity Read ↗

CYP2C19 genotypes in the pharmacokinetics/pharmacodynamics of proton pump inhibitor-based therapy of Helicobacter pylori infection.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.